PrEP - Pre-exposure prophylaxis
![September 2022: Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis](https://icap.columbia.edu/wp-content/uploads/Untitled-design-43-1080x675.png)
September 2022: Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
Article and Study Summary: Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis Published in: N Engl J Med. 2022;387(9):810-823 Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis Authors: Conradie F, Bagdasaryan TR, Borisov...Disrupting the status quo to achieve early inclusion of pregnant women in studies of new agents for prevention and treatment of HIV infection
Abstract: In 2021, long-acting cabotegravir (LA CAB) was approved by the United States Food and Drug Administration for an indication of pre-exposure prophylaxis in women. This is a first in what is hoped to be a robust pipeline of long-acting antiretroviral agents...![July 2022: Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya](https://icap.columbia.edu/wp-content/uploads/Untitled-design-16-1080x675.png)
July 2022: Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya
Article and Study Summary: Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial Published in: Lancet HIV. 2022;9(7):e464-e473 https://doi.org/10.1016/S2352-3018(22)00126-6 Authors: Ngure...![May/June 2022: Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial](https://icap.columbia.edu/wp-content/uploads/injection-1080x675.jpg)